Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 517-525, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (43)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weber, L. T.
Right arrow Articles by Tönshoff, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weber, L. T.
Right arrow Articles by Tönshoff, B.
Related Collections
Right arrow Pediatric Clinical Chemistry
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 2002;48:517-525.)
© 2002 American Association for Clinical Chemistry, Inc.

Comparison of the Emit Immunoassay with HPLC for Therapeutic Drug Monitoring of Mycophenolic Acid in Pediatric Renal-Transplant Recipients on Mycophenolate Mofetil Therapy

Lutz T. Weber1, Maria Shipkova2, Victor W. Armstrong2, Natalie Wagner1, Ekkehard Schütz2, Otto Mehls1, Lothar B. Zimmerhackl3, Michael Oellerich2 and Burkhard Tönshoff1a

1 Division of Pediatric Nephrology, University Children’s Hospital, Im Neuenheimer Feld 150, 69120 Heidelberg, Germany.

2 Department of Clinical Chemistry, Georg-August University Göttingen, 37070 Göttingen, Germany.

3 University Children’s Hospital Freiburg, 79106 Freiburg, Germany.

aAuthor for correspondence. Fax 49-6221-564203; e-mail Burkhard_Toenshoff{at}med.uni-heidelberg.de.

Background: HPLC is currently the preferred method for accurate measurement of mycophenolic acid (MPA). This study was designed to validate the Emit compared with HPLC in relation to clinical outcome measurements.

Methods: Pediatric renal-transplant recipients (n = 50) on an immunosuppressive triple regimen consisting of cyclosporin A, prednisone, and mycophenolate mofetil (600 mg/m2 twice per day) were investigated in an open-label prospective study. Pharmacokinetic profiles over 12 h were obtained at 1 week, 3 weeks, 3 months, and 6 months posttransplant. Plasma MPA was measured by both reversed-phase HPLC and the Emit immunoassay.

Results: There was an association between the risk of acute rejection episodes and low area under the curve values from t0 to t12h (AUC0–12) for MPA (MPA-AUC0–12) or predose concentrations of MPA derived from both HPLC and Emit measurements. According to ROC analysis, an AUC value of 33.8 mg · h/L for MPA from t0 to t12h (MPA-AUC0–12) determined by HPLC had a diagnostic sensitivity of 80% and a diagnostic specificity of 57%. The corresponding value of the Emit was 36.1 mg · h/L. For the predose concentration (MPA-c12), a concentration of 1.2 mg/L determined by HPLC and 1.4 mg/L determined by Emit gave a sensitivity of 80% and a specificity of 60%, respectively. There was no association of any pharmacokinetic variables derived from total MPA measurements with an increased risk of side effects related to mycophenolate mofetil.

Conclusions: The Emit assay appears to have a comparable diagnostic efficacy to HPLC for assessing the risk of acute rejection in pediatric renal-transplant recipients. However, because of the cross-reactivity of the antibody used in the Emit assay with the active MPA acyl glucuronide metabolite, the decision thresholds for the Emit were higher than those calculated from HPLC measurements.




The following articles in journals at HighWire Press have cited this article:


Home page
 CJASNHome page
H. Jeong and B. Kaplan
Therapeutic Monitoring of Mycophenolate Mofetil
Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 184 - 191.
[Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
Y.-M. Ku, M. McCartan, and D. Collier
Clinical Pharmacokinetic and Pharmacodynamic Monitoring for Mycophenolate Mofetil
Journal of Pharmacy Practice, December 1, 2005; 18(6): 422 - 431.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R. G Morris
Immunosuppressant Drug Monitoring: Is the Laboratory Meeting Clinical Expectations?
Ann. Pharmacother., January 1, 2005; 39(1): 119 - 127.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
B. Lumbreras-Lacarra, J. M. Ramos-Rincon, and I. Hernandez-Aguado
Methodology in Diagnostic Laboratory Test Research in Clinical Chemistry and Clinical Chemistry and Laboratory Medicine
Clin. Chem., March 1, 2004; 50(3): 530 - 536.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
I. Neumann, M. Haidinger, H. Jager, H. Grutzmacher, A. Griesmacher, M. M. Muller, P. M. Bayer, and F. Thomas Meisl
Pharmacokinetics of Mycophenolate Mofetil in Patients with Autoimmune Diseases Compared Renal Transplant Recipients
J. Am. Soc. Nephrol., March 1, 2003; 14(3): 721 - 727.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.